12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

USL261: Extension study started

Upsher-Smith began an open-label extension of the double-blind, placebo-controlled, international Phase III ARTEMIS1 trial to evaluate USL261 in about 155 patients with partial or generalized seizures on stable...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >